Short Interest in Windtree Therapeutics, Inc. (NASDAQ:WINT) Decreases By 76.2%

Windtree Therapeutics, Inc. (NASDAQ:WINT) was the recipient of a large drop in short interest in April. As of April 15th, there was short interest totalling 66,500 shares, a drop of 76.2% from the March 31st total of 279,300 shares. Based on an average daily volume of 2,740,000 shares, the days-to-cover ratio is currently 0.0 days. Approximately 8.9% of the company’s stock are short sold.

Windtree Therapeutics Price Performance

Windtree Therapeutics stock opened at $1.21 on Monday. The stock has a market capitalization of $906,290.00, a price-to-earnings ratio of -0.07 and a beta of 0.91. Windtree Therapeutics has a 1-year low of $1.01 and a 1-year high of $737.44. The business has a fifty day moving average price of $1.94 and a 200-day moving average price of $14.42.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Windtree Therapeutics stock. Renaissance Technologies LLC bought a new position in shares of Windtree Therapeutics, Inc. (NASDAQ:WINT) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 119,266 shares of the company’s stock, valued at approximately $42,000. Renaissance Technologies LLC owned 1.08% of Windtree Therapeutics as of its most recent SEC filing. 29.33% of the stock is currently owned by institutional investors and hedge funds.

Windtree Therapeutics Company Profile

Windtree Therapeutics, Inc, a biotechnology company, focuses on the development of therapeutics for the treatment of acute cardiovascular diseases. The company’s lead product candidate is istaroxime, which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as for the treatment of early cardiogenic shock.